SCHEMBL14366289

SCHEMBL14366289

CN(C)C(=N)NCCCC(NC(=O)c1ccccc1)C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ FOLH1 Q04609 8/20 0.45
▸ CA2 P00918 1/20 0.44
▸ C3AR1 Q16581 2/20 0.44
▸ ALB P02768 1/20 0.43
▸ PDE4A P27815 1/20 0.43
▸ PDE4B Q07343 1/20 0.43
▸ PDE4C Q08493 1/20 0.43
▸ PDE4D Q08499 1/20 0.43
▸ PADI6 Q6TGC4 1/20 0.43
▸ PADI1 Q9ULC6 1/20 0.43
▸ PADI3 Q9ULW8 1/20 0.43
▸ PADI4 Q9UM07 1/20 0.43
▸ PADI2 Q9Y2J8 1/20 0.43
▸ ACHE P22303 2/20 0.42
▸ BCHE P06276 1/20 0.42
▸ TDP1 Q9NUW8 1/20 0.42
▸ LMNA P02545 1/20 0.42
▸ HSD17B10 Q99714 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1983969 0.86 FOLH1 (0.47) FOLH1CA2C3AR1ALBPDE4A
SCHEMBL12560085 0.86 FOLH1 (0.47) FOLH1CA2C3AR1ALBPDE4A
SCHEMBL10801725 0.84 FOLH1 (0.59) FOLH1
SCHEMBL8975695 0.84 FOLH1 (0.59) FOLH1
SCHEMBL14366288 0.84 FOLH1 (0.46) FOLH1CA2C3AR1ALBPDE4A
SCHEMBL188590 0.83 C3AR1 (0.52) FOLH1CA2C3AR1ALBPDE4A
SCHEMBL7925397 0.83 C3AR1 (0.52) FOLH1CA2C3AR1ALBPDE4A
SCHEMBL188589 0.83 C3AR1 (0.52) FOLH1CA2C3AR1ALBPDE4A
Alcohol SCHEMBL29029781 0.81 CA2 (0.49) FOLH1CA2C3AR1PDE4APDE4B
Alcohol SCHEMBL2258594 0.81 CA2 (0.49) FOLH1CA2C3AR1PDE4APDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070276040-A1 Peptidyl Arginine Deiminase Type IV Inhibitor YOKOHAMA CITY UNIVERISITY (JP) 2007-11-29 — — US disclosed
US-20070276040-A1 Peptidyl Arginine Deiminase Type IV Inhibitor YOKOHAMA CITY UNIVERISITY (JP) 2007-11-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070276040-A1 Peptidyl Arginine Deiminase Type IV Inhibitor PADI4, PADI1, PADI2 FOLH1 1237/4885CA2 545/4885C3AR1 581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback